Carrollton-based Gradalis, Inc., a clinical-stage biotechnology company developing personalized anti-cancer therapies, has named Steven D. Weinstein as its new chief executive officer.
Weinstein brings more than 20 years as a life science venture capital investor and company builder.
As managing director of the Novartis Venture Fund for 12 years, he was actively engaged in all investment decisions across the $800M global portfolio, Gradalis said. Prior to Novartis, Weinstein was part of the life science team at Prism Venture Partners, a $1.25 billion family of funds. He began his venture career as a Kauffman Fellow with Mid-Atlantic Venture Funds.
